Beam Therapeutics Inc. vs Pfizer, Inc. — Stock Comparison

BEAM
Beam Therapeutics Inc.
$30.70
▲ 1.22%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
Pfizer, Inc.
PFE6.5/10vs 6/10

Q·Score Breakdown

6
Neutral
Overall
6.5
Neutral
1.1
Quality
7.4
8.7
Health
7
7.2
Growth
5.6
6.5
Valuation
6.7
8
Sentiment
5.2
BEAM

Clean balance sheet with low leverage (0.1× debt-to-equity).

currently unprofitable (-57% margin).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $51.20 (+66.8%)
15 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

BEAM
PFE
Trailing P/E
19.4×
-7.0×
Forward P/E
9.4×
-57.2%
Profit Margin
12.4%
-193.1%
Gross Margin
75.8%
-8.1%
ROE
8.9%
279.5%
Revenue Growth
-1.2%
Earnings Growth
2.19
Beta
0.39
Price / Book
$3.2B
Market Cap
$149.8B
$15 – $36
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →